PRRT2 and liver cancer: To confirm the Sp1 and PKC-mediated enhanced expression of TMBIM6, tissue sections of human breast, prostate, and liver cancers were procured and performed an immunohistochemistry analysis using PKCι-, Sp1-, and TMBIM6-specific antibodies.